ArticleFrontiers in immunology2026

A real-world study of ublituximab based on the WHO-VigiAccess and U.S. food and drug administration's adverse event reporting system databases.

Jiagnang Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.